GeneTex is leveraging its proprietary production platform and rigorous validation protocols to create reliable recombinant monoclonal antibodies for detection of protein post-translational modifications (PTMs).
Post-translational modifications (PTMs) are covalent enzymatic modifications that occur after protein biosynthesis and modulate protein conformation, stability, localization, and interaction networks. Key PTMs—including phosphorylation, ubiquitination, acetylation, methylation, glycosylation, and SUMOylation—act as dynamic modulators of proteostasis and signal transduction. These modifications, often reversible and combinatorial, orchestrate complex cellular processes such as cell cycle regulation, transcriptional control, immune surveillance, and apoptosis (1).
Phosphorylation, mediated by kinases and counteracted by phosphatases, alters protein activity and mediates rapid signaling cascades. Ubiquitination regulates protein degradation via the ubiquitin-proteasome system, essential for removing damaged or misfolded proteins and regulating protein turnover (2). Acetylation and methylation, particularly on histone tails, reshape chromatin structure and influence transcriptional accessibility. Glycosylation and SUMOylation contribute to protein trafficking, stability, and intracellular signaling fidelity. Importantly, PTMs often function in concert with interdependent modifications creating a highly nuanced regulatory code (3).
Aberrations in PTM machinery are increasingly linked to pathological states. Oncogenic signaling frequently involves constitutive phosphorylation or evasion of ubiquitin-mediated degradation. PTMs also play pivotal roles in host-pathogen interactions, as exemplified by SARS-CoV-2 infection, where viral and host PTM networks are rewired to favor viral replication and immune evasion (4). Additionally, the evolutionary plasticity of PTMs enables functional diversification across taxa, underscoring their biological importance (5).
The study of PTM-dependent protein–protein interactions (PPIs) is revealing new regulatory nodes and therapeutic targets, though clear interpretation remains challenging due to PTM heterogeneity and context dependence (6).
To support research into PTM-dependent networks and signaling, GeneTex is establishing a comprehensive collection of highly validated recombinant monoclonal antibodies (recmAbs) targeting specific PTM epitopes. These reagents expand GeneTex’s existing catalog of polyclonal and mouse monoclonal PTM antibodies and offer the additional benefits of lot-to-lot consistency, stable supply, and scalability. Optimized for applications including western blot, immunoprecipitation, immunocytochemistry, and immunohistochemistry, these reagents facilitate precise PTM detection across diverse experimental systems.
To learn more about GeneTex’s recombinant antibodies for PTM research, please see the highlighted products below, check out our flyer, or contact us for more information.
We gladly support you by keeping you updated on our latest products and the developments around our services.
Direct contact technical support
Find products for your research
